We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-19.26%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.5B
AUM Growth
-$54.4M
(-3.5%)
Cap. Flow
+$398M
Cap. Flow
% of AUM
26.54%
Top 10 Holdings %
Top 10 Hldgs %
91.37%
Holding
30
New
1
Increased
18
Reduced
3
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$227M |
| 2 |
Brookfield
BN
|
+$79.3M |
| 3 |
Apple
AAPL
|
+$41.1M |
| 4 |
Cable One
CABO
|
+$17M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$7.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Milestone Pharmaceuticals
MIST
|
+$6.13M |
| 2 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$2.36M |
| 3 |
Inspire Medical Systems
INSP
|
+$1.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.81% |
| 2 | Communication Services | 8.18% |
| 3 | Technology | 6.92% |
| 4 | Financials | 4.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vanguard Morningstar Total Stock Market ETF
VTI
$657B
| $746M | 49.82% |
5,790,400
+1,465,200
| +34% | +$227M |
|
2
Inogen
INGN
$174M
| $183M | 12.24% |
3,549,321
| – | – |
|
|
3
Cable One
CABO
$224M
| $123M | 8.18% |
74,595
+10,648
| +17% | +$17M |
|
|
4
Apple
AAPL
$4.9T
| $104M | 6.92% |
1,630,424
+559,272
| +52% | +$41.1M |
|
|
5
Brookfield
BN
$103B
| $60.4M | 4.03% |
5,738,049
+3,852,785
| +204% | +$79.3M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $38.8M | 2.59% |
2,645,446
| – | – |
|
7
Mirum Pharmaceuticals
MIRM
$6.87B
| $34.2M | 2.28% |
2,445,147
| – | – |
|
|
GRTX
8
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $32.4M | 2.16% |
3,409,021
| – | – |
|
9
Akebia Therapeutics
AKBA
$362M
| $25.7M | 1.72% |
3,393,039
+293,039
| +9% | +$2.28M |
|
|
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
| $21.4M | 1.43% |
2,320,026
+2,156
| +0.1% | +$20.5K |
|
|
SPNE
11
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $14M | 0.94% |
1,715,431
+407,394
| +31% | +$5.36M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $13.7M | 0.91% |
234,267
+63,600
| +37% | +$4.09M |
|
13
SI-BONE Inc
SIBN
$798M
| $11.6M | 0.77% |
971,390
+78,706
| +9% | +$1.45M |
|
|
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
| $10.1M | 0.68% |
750,974
+80,938
| +12% | +$1.54M |
|
|
15
Inspire Medical Systems
INSP
$1.44B
| $9.32M | 0.62% |
154,622
-20,378
| -12% | -$1.51M |
|
16
Spero Therapeutics
SPRO
$69.5M
| $7.52M | 0.5% |
931,099
| – | – |
|
|
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $7.12M | 0.48% |
151,816
+121,468
| +400% | +$7.78M |
|
18
Corvus Pharmaceuticals
CRVS
$1.11B
| $6.18M | 0.41% |
2,927,560
| – | – |
|
|
SILK
19
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $5.86M | 0.39% |
186,042
-58,958
| -24% | -$2.36M |
|
|
ETTX
20
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $5.76M | 0.38% |
2,181,843
| – | – |
|
|
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
| $5.52M | 0.37% |
223,184
+187,484
| +525% | +$6.83M |
|
|
CNST
22
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $5.29M | 0.35% |
+168,381
| New | +$5.85M |
|
23
Protagonist Therapeutics
PTGX
$8.92B
| $4.93M | 0.33% |
697,899
+218,825
| +46% | +$1.64M |
|
|
XENT
24
DELISTED
Intersect ENT, Inc
XENT
| $4.39M | 0.29% |
370,595
+152,886
| +70% | +$3.39M |
|
|
25
Milestone Pharmaceuticals
MIST
$143M
| $3.83M | 0.26% |
2,080,585
-353,885
| -15% | -$6.13M |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q1 2020 Portfolio in Review
As of Q1 2020, Novo Holdings A/S held 30 positions worth $1.5B, down 3.5% from $1.55B the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Novo Holdings A/S deployed $398M of net new capital in Q1 2020, opening 1 new position and adding to 18 existing holdings. Its largest new stake was Constellation Pharmaceuticals, Inc.: 168,381 shares worth $5.29M.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 38% a quarter earlier, followed by Communication Services and Technology.
On the sell side, the largest reduction was Milestone Pharmaceuticals, an estimated $6.13M trimmed.
- Novo Holdings A/S's largest Q1 2020 buy was Constellation Pharmaceuticals, Inc.: 168,381 shares worth $5.29M.
- Novo Holdings A/S added most to Vanguard Morningstar Total Stock Market ETF in Q1 2020, an estimated $227M increase.
- Novo Holdings A/S's biggest Q1 2020 reduction was Milestone Pharmaceuticals, cutting an estimated $6.13M.
- Novo Holdings A/S's ten largest holdings make up 91% of its $1.5B portfolio in Q1 2020.
- Novo Holdings A/S opened 1 new position and closed 0 in Q1 2020.
- Novo Holdings A/S's portfolio value fell 3.5% quarter-over-quarter to $1.5B.
Based on Novo Holdings A/S's 13F filing for Q1 2020, filed 15 May 2020.